Assess the latest evidence about investigational agents with unique mechanisms of action in late-stage development for ulcerative colitis (UC) and evaluate new clinical data on the efficacy and safety of therapeutic agents that target the immunological pathways of UC.
More information
Learning objectives
Upon successful completion of this educational activity, participants should be better able to:
- Assess the latest evidence about investigational agents with unique mechanisms of action in late-stage development for the treatment of moderate to severe ulcerative colitis.
- Evaluate new clinical data on the efficacy and safety of therapeutics that target immunological pathways in the treatment of moderate to severe ulcerative colitis.
- Compare therapeutic regimens for moderate to severe ulcerative colitis in terms of their ability to improve outcomes in patients who are tumor necrosis factor (TNF inhibitor)-naïve, as well as those who have received TNF inhibitors.
Course director and faculty
Activity Chair
Stephen B. Hanauer, MD
Clifford Joseph Barborka Professor of Medicine
Northwestern University Feinberg School of Medicine
Medical Director, Digestive Health Center
Chicago, IL
Faculty
Christina Y. Ha, MD, FACG, AGAF
Associate Professor of Medicine
Inflammatory Bowel Disease Center
Cedars-Sinai
Los Angeles, CA
Bruce E. Sands, MD, MS
Chief, Dr. Henry D. Janowitz Division of Gastroenterology
Dr. Burrill B. Crohn Professor of Medicine
Icahn School of Medicine at Mount Sinai Hospital and
Mount Sinai Health System
New York, NY
Accreditation and Designation Statement
The American Gastroenterological Association (AGA) Institute is accredited by the Accreditation Council
for Continuing Medical Education to provide continuing medical education for physicians.
The AGA Institute designates this enduring material for a maximum of 7.50 AMA PRA Category
1 Credits™. Physicians should claim only the credit commensurate with the extent of their
participation in the activity.
In accordance with the ACCME’s Standards for Commercial Support of Continuing Medical Education, all
faculty and planning partners must disclose any financial relationship(s) or other relationship(s) held
within the past 12 months. The AGA Institute implements a mechanism to identify and resolve all conflicts
of interest prior to delivering the educational activity to learners.
CME expiration date: October 31, 2021
Activity Chair and Faculty report the following relationship(s)
Christina Y. Ha, MD, FACG, AGAF
Consulting Fee: AbbVie, Genentech, IBD Remedy, Imedex, Janssen, Pfizer, Prova Education, Salix, Takeda
Speakers Bureau: AbbVie
Stephen B. Hanauer, MD
Consulting Fee: AbbVie, Allergan, Amgen, Arena Pharmaceuticals, Bristol-Myers Squibb, Celgene, Celltrion, Genentech, Gilead, GlaxoSmithKline, Janssen, Lilly, Merck, Nestle, Novartis, Pfizer, Progenity, Prometheus, Receptos, Salix, Samsung Bioepis, Seres Therapeutics, Takeda, TiGenix, UCB Pharma, VHsquared
Speakers Bureau: AbbVie, Janssen, Takeda
Contracted Research: (paid to institution): AbbVie, Allergan, Amgen, Celgene, Genentech, GlaxoSmithKline, Janssen, Lilly, Novartis, Pfizer, Prometheus, Receptos, Takeda, UCB Pharma
Data and Safety Monitoring Board: Arena Pharmaceuticals, Bristol-Myers Squibb
Bruce E. Sands, MD, MS
Consulting Fee: AbbVie, Arena Pharmaceuticals, AstraZeneca, Boehringer-Ingelheim, Boston Pharmaceuticals, Celltrion, Genentech, F. Hoffmann-La Roche AG, Immunic AG, Ironwood Pharmaceuticals, Janssen, Lilly, Morphic Therapeutic, Oppilan, OSE Immunotherapeutics, Otsuka, Pfizer, Prometheus, RedHill Biopharma, Shire, Takeda, Target PharmaSolutions, Theravance
